Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints
NCT04871854
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
Tocilizumab
DRUG:
traditional Covid -19 therapy
Sponsor
Beni-Suef University